{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:28Z","timestamp":1791920908133,"version":"4.3.4"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jsbmb.2022.106245","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T11:45:00Z","timestamp":1672746300000},"page":"106245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Secosteroid\u2013quinoline hybrids as new anticancer agents"],"prefix":"10.1016","volume":"228","author":[{"given":"Alexey I.","family":"Ilovaisky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Scherbakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina M.","family":"Merkulova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena I.","family":"Chernoburova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina A.","family":"Shchetinina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga E.","family":"Andreeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana I.","family":"Salnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor V.","family":"Zavarzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander O.","family":"Terent\u2019ev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2022.106245_bib1","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jsbmb.2022.106245_bib2","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/jnci\/94.20.1537","article-title":"Impact of reporting delay and reporting error on cancer incidence rates and trends","volume":"94","author":"Clegg","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2022.106245_bib3","first-page":"2027","article-title":"The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity","volume":"4","author":"Frei","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2022.106245_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jsbmb.2022.106245_bib5","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1038\/s41388-019-0780-z","article-title":"Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer","volume":"38","author":"Clarke","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.jsbmb.2022.106245_bib6","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2174\/1871520617666171114111721","article-title":"Steroidal anticancer agents: an overview of estradiol-related compounds","volume":"18","author":"Minorics","year":"2018","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jsbmb.2013.05.011","article-title":"Current status on development of steroids as anticancer agents","volume":"137","author":"Gupta","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2022.106245_bib8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ejmech.2016.08.039","article-title":"Hybrid molecules: the privileged scaffolds for various pharmaceuticals","volume":"124","author":"Shaveta","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib9","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1002\/anie.200200553","article-title":"Natural product hybrids as new leads drug discovery","volume":"42","author":"Tietze","year":"2003","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jsbmb.2022.106245_bib10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1039\/b204748a","article-title":"Hybrid system through natural product leads: an approach towards new molecular entities","volume":"31","author":"Mehta","year":"2002","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jsbmb.2022.106245_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100682","article-title":"Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors","volume":"50","author":"Dallavalle","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.jsbmb.2022.106245_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejmech.2017.05.016","article-title":"Designing multi-targeted agents: an emerging anticancer drug discovery paradigm","volume":"136","author":"Fu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib13","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bmc.2007.02.021","article-title":"Hybrid molecules of estrone: new compounds with potential antibacterial, antifungal, and antiproliferative activities","volume":"15","author":"Adamec","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1039\/C2NP20082A","article-title":"Anticancer steroids: linking natural and semi-synthetic compounds","volume":"30","author":"Salvador","year":"2013","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.jsbmb.2022.106245_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112904","article-title":"Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors","volume":"209","author":"Bass","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejmech.2018.03.057","article-title":"Success stories of natural product-based hybrid molecules for multi-factorial diseases","volume":"151","author":"Choudhary","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115763","article-title":"Discovery of novel steroidal-chalcone hybrids with potent and selective activity against triple-negative breast cancer","volume":"28","author":"Hou","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1574885512666170109143715","article-title":"Steroid hybrid systems: new molecular entities with potential therapeutical spectrum","volume":"12","author":"Borah","year":"2017","journal-title":"Curr. Drug Ther."},{"key":"10.1016\/j.jsbmb.2022.106245_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2022.106245_bib20","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/jm501239f","article-title":"Discovery and development of Galeterone (TOK-001 or VN\/124-1) for the treatment of all stages of prostate cancer","volume":"58","author":"Njar","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib21","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ejmech.2014.07.044","article-title":"A review on anticancer potential of bioactive heterocycle quinoline","volume":"97","author":"Afzal","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib22","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1016\/j.arabjc.2016.10.009","article-title":"Comprehensive review on current developments of quinoline-based anticancer agents","volume":"12","author":"Jain","year":"2019","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2174\/1871520620666200908104303","article-title":"Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanistics \u2013 A Medicinal Perspective","volume":"21","author":"Sharma","year":"2021","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib24","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.2174\/1568026620999200917154225","article-title":"An overwiew of privileged scaffold: quinolines and isoquinolines in medicinal chemistry as anticancer agents","volume":"20","author":"Mao","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib25","doi-asserted-by":"crossref","first-page":"10187","DOI":"10.1002\/slct.202002790","article-title":"Navigating the synthesis of quinoline hybrid molecules as promising anticancer agents","volume":"5","author":"Panda","year":"2020","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.jsbmb.2022.106245_bib26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2022.106245_bib27","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2022.106245_bib28","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2022.106245_bib29","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2011-02-334904","article-title":"Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas","volume":"118","author":"Witzig","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jsbmb.2022.106245_bib30","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.steroids.2012.08.008","article-title":"A microwave promoted solvent-free approach to steroidal quinolines and their in vitro evaluation for antimicrobial activities","volume":"77","author":"Gogoi","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib31","doi-asserted-by":"crossref","first-page":"27501","DOI":"10.1039\/C6RA03910C","article-title":"Microwave-assisted one-pot synthesis of steroid\u2013quinoline hybrids and an evaluation of their antiproliferative activities on gynecological cancer cell lines","volume":"6","author":"Baji","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jsbmb.2022.106245_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2019.108465","article-title":"Synthesis of new steroidal quinolines with antitumor properties","volume":"151","author":"Yang","year":"2019","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cmdc.201600482","article-title":"Design of a mestranol 2-N-piperazino-substituted derivative showing potent and selective in vitro and in vivo activities in MCF-7 breast cancer models","volume":"12","author":"Perreault","year":"2017","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.steroids.2016.08.015","article-title":"Explorative study on the anticancer activity, selectivity and metabolic stability of related analogs of aminosteroid RM-133","volume":"115","author":"Perreault","year":"2016","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib35","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1016\/j.bmc.2014.09.026","article-title":"Chemical synthesis, cytotoxicity, selectivity and bioavailability of 5alpha-androstane-3alpha,17beta-diol derivatives","volume":"22","author":"Ayan","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.steroids.2014.01.008","article-title":"Chemical synthesis, NMR analysis and evaluation on a cancer xenograft model (HL-60) of the aminosteroid derivative RM-133","volume":"82","author":"Maltais","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2174\/1871520616666151120122120","article-title":"A review of the recent developments in synthetic anti-breast cancer agents","volume":"16","author":"Singh","year":"2016","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jsbmb.2005.01.028","article-title":"Structure\u2013activity relationships of 2-, 4-, or 6-substituted estrogens as aromatase inhibitors","volume":"96","author":"Numazawa","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2022.106245_bib39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jsbmb.2016.06.013","article-title":"Mechanism of antiproliferative action of a new d-secoestrone-triazole derivative in cervical cancer cells and its effect on cancer cell motility","volume":"165","author":"B\u00f3zsity","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2022.106245_bib40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2174\/13852728113176660147","article-title":"An overview of partial synthesis and transformations of secosteroids","volume":"18","author":"Penov Gasi","year":"2014","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.steroids.2017.12.002","article-title":"Identification of d-seco modified steroid derivatives with affinity for estrogen receptor \u03b1 and \u03b2 isoforms using a non-transcriptional fluorescent cell assay in yeast","volume":"130","author":"Beki\u0107","year":"2018","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.steroids.2019.03.004","article-title":"Synthesis, characterization and antiproliferative activity of seco analogues of brassinosteroids","volume":"146","author":"Kvasnica","year":"2019","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2020.108777","article-title":"Azasteroids from diosgenin: synthesis and evaluation of their antiproliferative activity","volume":"166","author":"Mart\u00ednez-Gallegos","year":"2021","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib44","article-title":"New A-homo lactam D-homo lactone androstane derivative: synthesis and evaluation of cytotoxic and anti-inflammatory activities in vitro","volume":"57","author":"Savi\u0107","year":"2020","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib45","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11224-016-0815-9","article-title":"Structural analysis and antitumor potential of novel 5,6-disubstituted-17a-homo-17-oxa-androstane derivatives","volume":"28","author":"Kuzminac","year":"2017","journal-title":"Struct. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.steroids.2018.03.009","article-title":"Anticancer activity of novel steroidal 6-substituted 4-en-3-one D-seco dinitriles","volume":"135","author":"Nikoli\u0107","year":"2018","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.molstruc.2019.03.055","article-title":"Structural, computational and anticancer activity studies of D-seco-17-mesyloxy androstane derivatives","volume":"1187","author":"Oklje\u0161a","year":"2019","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jsbmb.2022.106245_bib48","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3109\/14756366.2015.1050008","article-title":"Synthesis and in vitro pharmacological evaluation of N-[(1-benzyl-1,2,3-triazol-4-yl)methyl]-carboxamides on d-secoestrone scaffolds","volume":"31","author":"Szab\u00f3","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem"},{"key":"10.1016\/j.jsbmb.2022.106245_bib49","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0039-128X(03)00097-7","article-title":"Synthesis, X-ray crystal structure and biological activity of 16-amino-17-substituted-D-homo steroid derivatives","volume":"68","author":"Penov Gasi","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib50","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0045-2068(03)00101-9","article-title":"Synthesis, structure, and screening of estrogenic and antiestrogenic activity of new 3,17-substituted16,17-seco-estratriene derivatives","volume":"31","author":"Jovanovic-Santa","year":"2003","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib51","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bmc.2014.12.069","article-title":"Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identi\ufb01cation of a selective inhibitor of hormone-independent breast cancer cells","volume":"23","author":"Nikolic","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib52","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0039-128X(90)90045-D","article-title":"Synthesis and estrogen activity screening of some new D-secoestrone derivatives","volume":"55","author":"Petrovic","year":"1990","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.steroids.2014.08.026","article-title":"Antihormonal potential of selected D-homo and D-seco estratriene derivatives","volume":"97","author":"Jovanovic-Santa","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib54","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s00044-010-9442-y","article-title":"Evaluation of biological activity of new hemiesters of 17-hydroxy-16,17- secoestra-1,3,5(10)-triene-16-nitrile","volume":"20","author":"Jovanovic-\u0160anta","year":"2011","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.jsbmb.2022.106245_bib55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ejoc.201901701","article-title":"Regioselective Baeyer-Villiger oxidation of steroidal ketones into lactones by BF3\/H2O2 system","author":"Ilovaisky","year":"2020","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2021.106000","article-title":"Secosteroidal hydrazides: promising scaffolds for anti-breast cancer agents","volume":"214","author":"Ilovaisky","year":"2021","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2022.106245_bib57","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.2147\/DDDT.S380925","article-title":"Oral Selective Estrogen Receptor Degraders (SERDs) in breast cancer: advances, challenges, and current status","volume":"16","author":"Downton","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jsbmb.2022.106245_bib58","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2022.106245_bib59","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejmech.2019.05.027","article-title":"Natural products as multidrug resistance modulators in cancer","volume":"176","author":"Kumar","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib60","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1134\/S0006297918070015","article-title":"Recent advances in the studies of molecular mechanisms regulating multidrug resistance in cancer cells","volume":"83","author":"Stavrovskaya","year":"2018","journal-title":"Biochem. Mosc."},{"key":"10.1016\/j.jsbmb.2022.106245_bib61","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2174\/0929867325666180105103637","article-title":"ABC Transporters: regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma","volume":"26","author":"Ceballos","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jsbmb.2022.106245_bib62","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/OTT.S154378","article-title":"Transcriptional profiling of NCI\/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance","volume":"11","author":"Vert","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.jsbmb.2022.106245_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.steroids.2018.07.007","article-title":"3,20-Dihydroxy-13\u03b1-19-norpregna-1,3,5(10)-trienes. Synthesis, structures, and cytotoxic, estrogenic, and antiestrogenic effects","volume":"137","author":"Kuznetsov","year":"2018","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2022.106245_bib64","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1080\/14786419.2020.1826479","article-title":"Antiestrogenic and antiproliferative potency of secoisolariciresinol diglucoside derivatives on MCF-7 breast cancer cells","volume":"35","author":"Scherbakov","year":"2021","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.jsbmb.2022.106245_bib65","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1097-2765(03)00090-X","article-title":"Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling","volume":"11","author":"Reid","year":"2003","journal-title":"Mol. Cell"}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076022001960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076022001960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:10:18Z","timestamp":1760746218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076022001960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":65,"alternative-id":["S0960076022001960"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2022.106245","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secosteroid\u2013quinoline hybrids as new anticancer agents","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2022.106245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106245"}}